ChengDa Pharmaceuticals Co., Ltd. (SHE:301201)
China · Delayed Price · Currency is CNY 38.30
-0.35 (-0.91%)
At close: Feb 2, 2026
ChengDa Pharmaceuticals Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Net Income | -51.72 | -28.1 | 90.98 | 106.48 | 100.44 | 121.17 |
Depreciation & Amortization | 46.85 | 46.85 | 40.6 | 35.32 | 30.49 | 26.34 |
Other Amortization | 14.56 | 14.56 | 9.03 | 4.27 | 2.05 | 2.19 |
Loss (Gain) From Sale of Assets | -0.2 | -0.2 | 0.01 | 0.53 | 0.02 | -41.86 |
Asset Writedown & Restructuring Costs | 2.53 | 2.53 | 3.5 | 3.43 | 2.62 | 1.85 |
Loss (Gain) From Sale of Investments | -32.39 | -32.39 | -41.82 | -39.66 | - | - |
Provision & Write-off of Bad Debts | -1.71 | -1.71 | 1.06 | 1.05 | 1.42 | -1.05 |
Other Operating Activities | 35.51 | 3.35 | 0.69 | 7.98 | 3.11 | 3 |
Change in Accounts Receivable | -35.47 | -35.47 | -1.46 | -54.62 | -36.16 | 16.92 |
Change in Inventory | -12.59 | -12.59 | 28.79 | -60.33 | -47.35 | 8.32 |
Change in Accounts Payable | 71.65 | 71.65 | 60.38 | 42.12 | 26.19 | -8.45 |
Change in Other Net Operating Assets | 0.62 | 0.62 | 0.75 | 0.75 | 0.75 | 0.75 |
Operating Cash Flow | 37.19 | 28.65 | 192.07 | 47.67 | 83.14 | 128.97 |
Operating Cash Flow Growth | -64.09% | -85.08% | 302.96% | -42.67% | -35.53% | 91.00% |
Capital Expenditures | -211.7 | -286.36 | -224.67 | -205.69 | -138.7 | -63.81 |
Sale of Property, Plant & Equipment | 0.14 | 2.15 | 0.34 | 0.29 | 0.12 | 56.71 |
Investment in Securities | 449.91 | -956.05 | 776.89 | -822.46 | - | - |
Other Investing Activities | 24.32 | 30.79 | 41.82 | 39.23 | - | -3.08 |
Investing Cash Flow | 262.67 | -1,209 | 594.39 | -988.64 | -138.58 | -10.18 |
Short-Term Debt Issued | - | - | - | 1.02 | 78.98 | 48.48 |
Long-Term Debt Issued | - | 80.12 | - | - | - | - |
Total Debt Issued | 88.2 | 80.12 | - | 1.02 | 78.98 | 48.48 |
Short-Term Debt Repaid | - | - | - | -70 | -20 | -158.98 |
Total Debt Repaid | -30 | - | - | -70 | -20 | -158.98 |
Net Debt Issued (Repaid) | 58.2 | 80.12 | - | -68.98 | 58.98 | -110.5 |
Issuance of Common Stock | - | - | - | 1,638 | - | - |
Common Dividends Paid | -32.37 | -30.55 | -29.01 | -43.79 | -31.34 | -22.84 |
Other Financing Activities | 0.38 | -56.69 | - | - | - | 1.2 |
Financing Cash Flow | 25.83 | -7.12 | -29.01 | 1,526 | 27.65 | -132.14 |
Foreign Exchange Rate Adjustments | 1.04 | 2.21 | 0.8 | 1.23 | -0.73 | -1.57 |
Net Cash Flow | 326.73 | -1,186 | 758.26 | 585.94 | -28.52 | -14.92 |
Free Cash Flow | -174.51 | -257.72 | -32.6 | -158.03 | -55.56 | 65.16 |
Free Cash Flow Growth | - | - | - | - | - | 295.85% |
Free Cash Flow Margin | -46.60% | -77.36% | -7.87% | -38.41% | -13.36% | 17.47% |
Free Cash Flow Per Share | -1.15 | -1.70 | -0.21 | -1.04 | -0.48 | 0.56 |
Cash Income Tax Paid | 9.07 | 19.73 | 13.93 | 29.14 | 22.36 | 27.46 |
Levered Free Cash Flow | -213.02 | -233.21 | -46.73 | -191.77 | -98.29 | 57.1 |
Unlevered Free Cash Flow | -212.84 | -233.02 | -46.73 | -191.64 | -97.41 | 58.78 |
Change in Working Capital | 23.77 | 23.77 | 88.02 | -71.73 | -57.01 | 17.32 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.